CervarixTM

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, PapillomavirusPapillomavirus Vaccines

Phase 2

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

CompletedNCT00359619

GlaxoSmithKlineInfections, Papillomavirus, Papillomavirus Vaccines

Start: 2006-09-12End: 2007-01-30Updated: 2020-01-02

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

CompletedNCT00996125

GlaxoSmithKlineInfections, Papillomavirus

Start: 2009-10-24End: 2010-12-08Updated: 2018-08-17

Related Papers

Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

Asia-Pacific Journal of Clinical Oncology2020-08-112 citations

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

Human Vaccines & Immunotherapeutics2014-04-2926 citations